Sugi Predict

Sugi Predict / Compounds / SCHEMBL586118

SCHEMBL586118

SCHEMBL586118

O=Cc1ncccc1C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ NFE2L2 Q16236 10/20 0.48
▸ LMNA P02545 1/20 0.41
▸ EPHX2 P34913 1/20 0.40
▸ TRIM24 O15164 1/20 0.38
▸ TRIM33 Q9UPN9 1/20 0.38
▸ ERN1 O75460 1/20 0.38
▸ CTNNB1 P35222 1/20 0.37
▸ WNT3A P56704 1/20 0.37
▸ TRPV1 Q8NER1 2/20 0.37
▸ HSD11B1 P28845 1/20 0.36
▸ SLC40A1 Q9NP59 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22212665 0.85 NFE2L2 (0.39) NFE2L2EPHX2TRIM24TRIM33ERN1
SCHEMBL80776 0.80 TRIM24 (0.38) NFE2L2LMNATRIM24TRIM33
SCHEMBL1992349 0.80 NFE2L2 (0.47) NFE2L2LMNAEPHX2
SCHEMBL17317193 0.80 NFE2L2 (0.44) NFE2L2LMNAEPHX2CTNNB1WNT3A
SCHEMBL4762123 0.77 NFE2L2 (0.48) NFE2L2LMNAEPHX2TRPV1HSD11B1
SCHEMBL14686364 0.77 NFE2L2 (0.51) NFE2L2HSD11B1SLC40A1
SCHEMBL2092601 0.76 NFE2L2 (0.50) NFE2L2LMNAEPHX2HSD11B1
SCHEMBL27841616 0.76 LMNA (0.44) NFE2L2LMNAEPHX2CTNNB1WNT3A
SCHEMBL12472261 0.76 LMNA (0.44) NFE2L2LMNAEPHX2CTNNB1WNT3A
SCHEMBL21749326 0.76 DHODH (0.42) NFE2L2LMNAEPHX2TRPV1SLC40A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116854630-B Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections 吉利德科学公司 2026-05-19 — — CN disclosed
US-12600726-B2 Antagonists of the muscarinic acetylcholine receptor M4 VANDERBILT UNIVERSITY (US) 2026-04-14 — — US disclosed
US-12582645-B2 Chemokine CXCR4 receptor modulators and uses related thereto EMORY UNIVERSITY (US) 2026-03-24 — — US disclosed
WO-2025099451-A1 NEW COMPOUNDS AND METHODS Transition Bio Limited (GB) 2025-05-15 — — WO disclosed
CN-119954725-A TEAD inhibitors and uses thereof 医肯纳肿瘤学公司 2025-05-09 — — CN disclosed
US-20250136594-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-01 — — US disclosed
EP-4534528-A1 NOVEL SULFANONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF Korea Institute of Science and Technology (KR) 2025-04-09 — — EP disclosed
US-20250100999-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2025-03-27 — — US disclosed
CN-119604487-A Novel sulfimide derivative or pharmaceutically acceptable salt thereof and application thereof 韩国科学技术研究院 2025-03-11 — — CN disclosed
EP-4469438-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
US-20100216792-A1 Pesticidal arylpyrrolidines BAYER CROPSCIENCE AG (DE) 2010-08-26 — — US disclosed
US-20100216792-A1 Pesticidal arylpyrrolidines BAYER CROPSCIENCE AG (DE) 2010-08-26 — — US disclosed
US-20100160583-A1 Polymerisation of Ethylene and Alpha-Olefins with Pyridino-Iminophenol Complexes TOTAL PETROCHEMICALS RESEARCH FEULY (BE) 2010-06-24 — — US disclosed
CN-101679436-A Fused ring heterocycle kinase modulators SGX PHARMACEUTICALS INC 2010-03-24 — — CN disclosed
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-23 — — US disclosed
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-23 — — US disclosed
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-23 — — US disclosed
WO-2008124848-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 — — WO disclosed
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED CORPORATION (CA) 2008-10-16 — — US disclosed
US-7291631-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2007-11-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136594-A1 COMPOUNDS AND METHODS OF USE CNKSR1, UGT1A1, REV1 NFE2L2 2477/4885LMNA 936/4885EPHX2 543/4885
US-20100216792-A1 Pesticidal arylpyrrolidines DDT, AADAC, AHR NFE2L2 1233/4885LMNA 4457/4885EPHX2 1089/4885
US-20250100999-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS CYP11A1, CYP11B1, CYP11B2 NFE2L2 3107/4885LMNA 1143/4885EPHX2 1081/4885
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS MAP3K20, MAP3K19, MAP4K2 NFE2L2 2530/4885LMNA 3958/4885EPHX2 2754/4885
US-12600726-B2 Antagonists of the muscarinic acetylcholine receptor M4 CHRM3, CHRM4, CHRM2 NFE2L2 4482/4885LMNA 3802/4885EPHX2 1311/4885
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS CXCR4, CXCR1, CXCR3 NFE2L2 1764/4885LMNA 4691/4885EPHX2 1230/4885
US-12582645-B2 Chemokine CXCR4 receptor modulators and uses related thereto CXCR4, CXCR2, CXCR1 NFE2L2 1576/4885LMNA 4472/4885EPHX2 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.